Metronidazole Baxter (Metronidazole)

Metronidazole is taken up by anaerobic organisms and reduced by intracellular electron transport proteins. The reduced drug forms reactive nitro radicals that bind to DNA, causing strand breakage and inhibiting nucleic acid synthesis, which ultimately leads to cell death of the targeted microbes.

The dosage of Metronidazole Baxter is determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local treatment guidelines. Only a qualified health professional should set the dosing regimen.

Safety data for metronidazole in pregnancy are limited, and the drug is classified as pregnancy category unknown. It should be used only when the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should discuss possible infant exposure with their healthcare provider before use.

To request Metronidazole Baxter, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Metronidazole is a nitroimidazole that specifically targets anaerobic bacteria and certain protozoa, offering rapid bactericidal activity. Compared with broad‑spectrum beta‑lactams, it provides a narrower spectrum focused on anaerobes, often resulting in fewer disturbances to normal flora. It is frequently preferred when anaerobic coverage is the primary therapeutic goal.

Metronidazole Baxter should be stored below 25 °C, in its original packaging, protected from light, moisture and temperature extremes. Do not freeze the solution. Follow any additional handling instructions provided on the label to maintain product stability.

Metronidazole Baxter is supplied as a sterile intravenous solution. It is administered by a qualified healthcare professional through a controlled IV infusion, following aseptic technique and the dosing instructions prescribed for the specific infection being treated.

Serious adverse reactions can include peripheral neuropathy, seizures, severe allergic responses such as anaphylaxis, and hepatotoxicity. Patients should be monitored for neurological symptoms, liver function changes, and any signs of hypersensitivity throughout therapy.

Metronidazole Baxter is contraindicated in patients with a known hypersensitivity to metronidazole or other nitroimidazole compounds. Caution is also advised for individuals with severe hepatic impairment, and it should be avoided in those who have experienced a disulfiram‑like reaction to alcohol while on metronidazole.